Septic Shock Clinical Trial
Official title:
Expression of Protein Tyrosine Phosphatase 1B (PTP1B) and Body Composition Modification in Patients With Septic Shock
With a prevalence of more than 15% in ICU, septic shock today represents a real public health
problem and remains the leading cause of mortality in ICU. Undernutrition is characterized by
an alteration of the body composition and in particular by a loss of muscle mass. In
intensive care, there are indirect elements suggesting a link between loss of muscle mass and
prognosis.
Muscle mass results from a balance between the pathway of proteolysis and that of protein
synthesis, depending on many factors, not one of the most important are insulin. The protein
PTP1B (Protein Tyrosine Phosphatase 1B), by the dephosphorylation of its numerous substrates,
constitutes an endogenous regulator of numerous intracellular signaling pathways, including
that of insulin. PTP1B could play a role in the protein synthesis abnormalities observed
during sepsis leading clinically to impaired body composition including muscle body mass.
Therefore, we propose to study the association between PTP1B and loss of muscle mass in
patients in sepsis in resuscitation.
The intestinal barrier plays an essential role in protecting against microbial luminal flora
and the phenomenon of bacterial translocation. Zonulin is one of the major regulators of
tight junctions, important actors in the intestinal barrier function. The increase in plasma
zonulin levels, greater than 0.6 ng / mg, is directly correlated with increased intestinal
permeability (16). However, elevation of plasma zonulin has never been evaluated in septic
resuscitation patients. This is why we propose the evaluation of the association between
plasma zonulin and the loss of muscle mass in these resuscitation patients.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT03649633 -
Vitamin C, Steroids, and Thiamine, and Cerebral Autoregulation and Functional Outcome in Septic Shock
|
Phase 1/Phase 2 | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Completed |
NCT05629780 -
Temporal Changes of Lactate in CLASSIC Patients
|
N/A | |
Recruiting |
NCT04796636 -
High-dose Intravenous Vitamin C in Patients With Septic Shock
|
Phase 1 | |
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Recruiting |
NCT05066256 -
LV Diastolic Function vs IVC Diameter Variation as Predictor of Fluid Responsiveness in Shock
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 | |
Not yet recruiting |
NCT04516395 -
Optimizing Antibiotic Dosing Regimens for the Treatment of Infection Caused by Carbapenem Resistant Enterobacteriaceae
|
N/A | |
Recruiting |
NCT02899143 -
Short-course Antimicrobial Therapy in Sepsis
|
Phase 2 | |
Recruiting |
NCT02676427 -
Fluid Responsiveness in Septic Shock Evaluated by Caval Ultrasound Doppler Examination
|
||
Recruiting |
NCT02565251 -
Volemic Resuscitation in Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT02580240 -
Administration of Hydrocortisone for the Treatment of Septic Shock
|
N/A | |
Terminated |
NCT02335723 -
ASSET - a Double-Blind, Randomized Placebo-Controlled Clinical Investigation With Alteco® LPS Adsorber
|
N/A | |
Completed |
NCT02638545 -
Hemodynamic Effects of Dexmedetomidine in Septic Shock
|
Phase 3 | |
Not yet recruiting |
NCT02547467 -
TOADS Study: TO Assess Death From Septic Shock.
|
N/A | |
Completed |
NCT02079402 -
Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care
|
Phase 4 | |
Completed |
NCT02306928 -
PK Analysis of Piperacillin in Septic Shock Patients
|
N/A |